New shot aims to tame BK virus in transplant kidneys
NCT ID NCT07503561
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a new drug called AIC263029 is safe and can lower BK virus levels in kidney transplant recipients. About 24 adults who had a kidney transplant within the past year and have a first-time BK virus infection will receive weekly injections for 4 weeks. Researchers will compare the drug against a placebo to see if it reduces the virus without causing serious side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AIC263029
- What this could lead to
- If successful, this could point toward a treatment to control BK virus in kidney transplant patients, potentially reducing graft loss.
- What could go wrong
- This is an early-phase trial with only 24 participants, so results may not apply broadly. The drug may not lower virus levels or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BK VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can cord blood t cells be trained to stop viral infections after transplant?
- Can specially grown immune cells from donors beat viruses that won't go away?
- Can 'Supercharged' donor cells beat viruses that drugs Can't?
- Banked immune cells show promise against Life-Threatening viruses in transplant patients
- Donor immune cells take on tough viruses in transplant patients
- New study aims to unlock BK virus mysteries in kidney transplants